Fig. 6From: Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancerDFS analysis in ER+ and/or PR+ positive subgroup. a PFS: 10y endocrine therapy versus 5y endocrine therapy in ER+ and/or PR+ positive subgroup, b The recurrence rates in ER+ and/or PR+ positive subgroupBack to article page